[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Ciprofloxacin.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be decreased when combined with Ciprofloxacin.]
[J01GA01, streptomycin, Ciprofloxacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01CG01, sulbactam, Ciprofloxacin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01CA16, sulbenicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Sulbenicillin.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Ciprofloxacin.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Ciprofloxacin.]
[M04AB02, sulfinpyrazone, The metabolism of Sulfinpyrazone can be decreased when combined with Ciprofloxacin.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Ciprofloxacin.]
[M01AB02, sulindac, Sulindac may increase the neuroexcitatory activities of Ciprofloxacin.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Ciprofloxacin.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Ciprofloxacin.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Ciprofloxacin.]
[M01AX04, apazone, Azapropazone may increase the neuroexcitatory activities of Ciprofloxacin.]
[L01BB02, mercaptopurine, The serum concentration of Mercaptopurine can be increased when it is combined with Ciprofloxacin.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Ciprofloxacin.]
[J01CA15, talampicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Talampicillin.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Ciprofloxacin.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Ciprofloxacin.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ciprofloxacin.]
[B01AE07, dabigatran etexilate, Ciprofloxacin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Ciprofloxacin.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Tetracycline can be decreased when combined with Ciprofloxacin.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[N05AE05, lurasidone, The metabolism of Lurasidone can be decreased when combined with Ciprofloxacin.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Ciprofloxacin.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Ciprofloxacin.]
[R03DA07, theobromine, The serum concentration of Theobromine can be increased when it is combined with Ciprofloxacin.]
[R03DA04, theophylline, The serum concentration of Theophylline can be increased when it is combined with Ciprofloxacin.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be decreased when combined with Ciprofloxacin.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ciprofloxacin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Ciprofloxacin.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Thioridazine.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be decreased when combined with Ciprofloxacin.]
[G04BE06, moxisylyte, Ciprofloxacin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL03, tiapride, Ciprofloxacin may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[J01CA13, ticarcillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Ticarcillin.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Ciprofloxacin.]
[P01AB02, tinidazole, The metabolism of Tinidazole can be decreased when combined with Ciprofloxacin.]
[S01AA12, tobramycin, Ciprofloxacin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Ciprofloxacin.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Ciprofloxacin.]
[M02AA21, tolmetin, Tolmetin may increase the neuroexcitatory activities of Ciprofloxacin.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Ciprofloxacin.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ciprofloxacin.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Ciprofloxacin.]
[S01BA05, triamcinolone, The risk or severity of tendinopathy can be increased when Triamcinolone is combined with Ciprofloxacin.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Ciprofloxacin.]
[N05CD05, triazolam, The metabolism of Triazolam can be decreased when combined with Ciprofloxacin.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Ciprofloxacin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be decreased when combined with Ciprofloxacin.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[D07AC02, fluclorolone, The risk or severity of tendinopathy can be increased when Fluclorolone is combined with Ciprofloxacin.]
[R03BA07, mometasone, The risk or severity of tendinopathy can be increased when Mometasone is combined with Ciprofloxacin.]
[A03AA05, trimebutine, The metabolism of Trimebutine can be decreased when combined with Ciprofloxacin.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ciprofloxacin.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Ciprofloxacin.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Ciprofloxacin.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Ciprofloxacin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ciprofloxacin.]
[J01FA08, troleandomycin, The metabolism of Troleandomycin can be decreased when combined with Ciprofloxacin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Ciprofloxacin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Ciprofloxacin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Ciprofloxacin.]
[L01FX04, ipilimumab, Ciprofloxacin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Ciprofloxacin.]
[R02AA14, oxyquinoline, Ciprofloxacin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Abiraterone can be decreased when combined with Ciprofloxacin.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Ciprofloxacin.]
[J05AP03, boceprevir, The metabolism of Boceprevir can be decreased when combined with Ciprofloxacin.]
[J05AP02, telaprevir, The metabolism of Telaprevir can be decreased when combined with Ciprofloxacin.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be increased when it is combined with Ciprofloxacin.]
[S01AA28, vancomycin, Ciprofloxacin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Ciprofloxacin.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Ciprofloxacin.]
[R03AC18, indacaterol, The metabolism of Indacaterol can be decreased when combined with Ciprofloxacin.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Ciprofloxacin.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Ciprofloxacin.]
[N06AX09, viloxazine, Ciprofloxacin may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Ciprofloxacin.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Ciprofloxacin.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Ciprofloxacin.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[A11HA03, vitamin E, The metabolism of Vitamin E can be decreased when combined with Ciprofloxacin.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Ciprofloxacin.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Ciprofloxacin.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Indinavir can be decreased when combined with Ciprofloxacin.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Ciprofloxacin.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ciprofloxacin.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Ciprofloxacin.]
[M05BA05, tiludronic acid, Ciprofloxacin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Ciprofloxacin may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Ciprofloxacin.]
[A02BC04, rabeprazole, Ciprofloxacin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Ciprofloxacin.]
[V03AC02, deferiprone, Ciprofloxacin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Ciprofloxacin.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Ciprofloxacin.]
[J01DH04, doripenem, Ciprofloxacin may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be decreased when combined with Ciprofloxacin.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Atropine.]
[M01CB03, auranofin, Ciprofloxacin may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Ciprofloxacin.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Ciprofloxacin.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Ciprofloxacin.]
[H02AB11, prednylidene, The risk or severity of tendinopathy can be increased when Prednylidene is combined with Ciprofloxacin.]
[B03XA04, peginesatide, Ciprofloxacin may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Ciprofloxacin may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Ciprofloxacin.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01CA09, azlocillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Azlocillin.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Ciprofloxacin.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Ciprofloxacin.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Ciprofloxacin.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be decreased when combined with Ciprofloxacin.]
[V03AX03, cobicistat, The metabolism of Cobicistat can be decreased when combined with Ciprofloxacin.]
[J05AJ02, elvitegravir, The metabolism of Elvitegravir can be decreased when combined with Ciprofloxacin.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Ciprofloxacin.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Ciprofloxacin.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AA01, aldosterone, The risk or severity of tendinopathy can be increased when Aldosterone is combined with Ciprofloxacin.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Ciprofloxacin.]
[D02BA02, octinoxate, Ciprofloxacin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Nelfinavir can be decreased when combined with Ciprofloxacin.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Ciprofloxacin.]
[N04BD02, rasagiline, The serum concentration of Rasagiline can be increased when it is combined with Ciprofloxacin.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be decreased when combined with Ciprofloxacin.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Ciprofloxacin.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Ciprofloxacin.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Ciprofloxacin.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Ciprofloxacin.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Ciprofloxacin.]
[V09IX04, fluorodeoxyglucose F18, Ciprofloxacin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Ciprofloxacin.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Ciprofloxacin.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Ciprofloxacin.]
[V08CA11, gadofosveset, Ciprofloxacin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Ciprofloxacin.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Ciprofloxacin.]
[A16AX08, teduglutide, Ciprofloxacin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Ciprofloxacin.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Bedaquiline.]
[C04AX11, bencyclane, The metabolism of Bencyclane can be decreased when combined with Ciprofloxacin.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Ciprofloxacin.]
[A16AX09, glycerol phenylbutyrate, Ciprofloxacin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Ciprofloxacin.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Ciprofloxacin.]
[N02BA10, benorilate, Benorilate may increase the neuroexcitatory activities of Ciprofloxacin.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Gemifloxacin.]
[A12CC09, magnesium orotate, Magnesium orotate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ciprofloxacin.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Ciprofloxacin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Ciprofloxacin.]
[L03AA12, ancestim, Ciprofloxacin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Ciprofloxacin.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Ciprofloxacin.]
[A12CC05, magnesium aspartate, Magnesium aspartate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ciprofloxacin.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be decreased when combined with Ciprofloxacin.]
[R02AX03, benzydamine, Benzydamine may increase the neuroexcitatory activities of Ciprofloxacin.]
[L01EE01, trametinib, Ciprofloxacin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Ciprofloxacin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Ciprofloxacin.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Ciprofloxacin.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Ciprofloxacin.]
[C02KX04, macitentan, The metabolism of Macitentan can be decreased when combined with Ciprofloxacin.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Ciprofloxacin.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Ciprofloxacin.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be decreased when combined with Ciprofloxacin.]
[J05AP05, simeprevir, The metabolism of Simeprevir can be decreased when combined with Ciprofloxacin.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AP08, sofosbuvir, Ciprofloxacin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Ciprofloxacin.]
[C01CA27, droxidopa, Ciprofloxacin may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, The serum concentration of Tasimelteon can be increased when it is combined with Ciprofloxacin.]
[L04AA32, apremilast, The metabolism of Apremilast can be decreased when combined with Ciprofloxacin.]
[L02BG02, formestane, Ciprofloxacin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of tendinopathy can be increased when Betamethasone is combined with Ciprofloxacin.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Ciprofloxacin.]
[V03AB34, fomepizole, Ciprofloxacin may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The metabolism of Bezafibrate can be decreased when combined with Ciprofloxacin.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Ciprofloxacin.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Ciprofloxacin.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Ciprofloxacin.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ciprofloxacin.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Ciprofloxacin.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Ciprofloxacin.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ciprofloxacin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ciprofloxacin.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Ciprofloxacin.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Ciprofloxacin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Ciprofloxacin.]
[A06AH03, naloxegol, The metabolism of Naloxegol can be decreased when combined with Ciprofloxacin.]
[A11HA08, tocophersolan, The metabolism of Tocofersolan can be decreased when combined with Ciprofloxacin.]
[L04AX05, pirfenidone, The serum concentration of Pirfenidone can be increased when it is combined with Ciprofloxacin.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Ciprofloxacin.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, Ciprofloxacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Ciprofloxacin.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Ciprofloxacin.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Ciprofloxacin.]
[B01AF03, edoxaban, Ciprofloxacin may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be decreased when combined with Ciprofloxacin.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Ciprofloxacin.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Ciprofloxacin.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Ciprofloxacin.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Ciprofloxacin.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Ciprofloxacin.]
[C01EB17, ivabradine, The metabolism of Ivabradine can be decreased when combined with Ciprofloxacin.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Ciprofloxacin.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Ciprofloxacin.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Ciprofloxacin.]
[A04AD14, rolapitant, The metabolism of Rolapitant can be decreased when combined with Ciprofloxacin.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Ciprofloxacin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Ciprofloxacin.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Ciprofloxacin.]
[M02AA25, aceclofenac, Aceclofenac may increase the neuroexcitatory activities of Ciprofloxacin.]
[M01AB11, acemetacin, Acemetacin may increase the neuroexcitatory activities of Ciprofloxacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Ciprofloxacin.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Ciprofloxacin.]
[V03AB37, idarucizumab, Ciprofloxacin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Ciprofloxacin.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be decreased when combined with Ciprofloxacin.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Ciprofloxacin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ciprofloxacin.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Ciprofloxacin.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Ciprofloxacin.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Ciprofloxacin.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Ciprofloxacin.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Ciprofloxacin.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Ciprofloxacin.]
[M04AB05, lesinurad, Ciprofloxacin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Ciprofloxacin.]
[J05AP11, grazoprevir, The metabolism of Grazoprevir can be decreased when combined with Ciprofloxacin.]
[M01AE16, alminoprofen, Alminoprofen may increase the neuroexcitatory activities of Ciprofloxacin.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Ciprofloxacin.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Ciprofloxacin.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Ciprofloxacin.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Ciprofloxacin.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ciprofloxacin.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be decreased when combined with Ciprofloxacin.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Ciprofloxacin.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Ciprofloxacin.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Ciprofloxacin.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Ciprofloxacin.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Ciprofloxacin.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Ciprofloxacin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Artemether.]
[M02AA03, clofezone, Ciprofloxacin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ciprofloxacin.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Ciprofloxacin.]
[J01CE04, azidocillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Azidocillin.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Ciprofloxacin.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Ciprofloxacin.]
[J01CA06, bacampicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Bacampicillin.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Ciprofloxacin.]
[A07EC04, balsalazide, Balsalazide may increase the neuroexcitatory activities of Ciprofloxacin.]
[R03DA08, bamifylline, The serum concentration of Bamifylline can be increased when it is combined with Ciprofloxacin.]
[A06AH05, naldemedine, Ciprofloxacin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ciprofloxacin.]
[N06BC01, caffeine, The serum concentration of Caffeine can be increased when it is combined with Ciprofloxacin.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Benazepril is combined with Ciprofloxacin.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Ciprofloxacin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Calcitriol can be decreased when combined with Ciprofloxacin.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P01CA02, benznidazole, Ciprofloxacin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J05AF06, abacavir, Ciprofloxacin may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Tipranavir can be decreased when combined with Ciprofloxacin.]
[D11AX03, calcium gluconate, Calcium gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Ciprofloxacin.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ciprofloxacin.]
[A12AA01, calcium phosphate, Calcium Phosphate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Ciprofloxacin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Ciprofloxacin.]
[N04BD03, safinamide, The metabolism of Safinamide can be decreased when combined with Ciprofloxacin.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Ciprofloxacin.]
[L01BC06, capecitabine, Ciprofloxacin may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Ciprofloxacin.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Ciprofloxacin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Ciprofloxacin.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Ciprofloxacin.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Ciprofloxacin.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The metabolism of Bisoprolol can be decreased when combined with Ciprofloxacin.]
[J05AG03, efavirenz, The metabolism of Efavirenz can be decreased when combined with Ciprofloxacin.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[N05CD09, brotizolam, The metabolism of Brotizolam can be decreased when combined with Ciprofloxacin.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of tendinopathy can be increased when Budesonide is combined with Ciprofloxacin.]
[M01AB07, bumadizone, Bumadizone may increase the neuroexcitatory activities of Ciprofloxacin.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Ciprofloxacin.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Ciprofloxacin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Ciprofloxacin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Ciprofloxacin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ciprofloxacin.]
[C09AA01, captopril, The risk or severity of hyperkalemia can be increased when Captopril is combined with Ciprofloxacin.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Ciprofloxacin.]
[N03AF01, carbamazepine, The serum concentration of Carbamazepine can be increased when it is combined with Ciprofloxacin.]
[A06AC08, calcium polycarbophil, Calcium polycarbophil can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01CA03, carbenicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Carbenicillin.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Ciprofloxacin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Carbinoxamine.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Ciprofloxacin.]
[B02BX09, fostamatinib, The metabolism of Fostamatinib can be decreased when combined with Ciprofloxacin.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Ciprofloxacin.]
[L04AA37, baricitinib, The metabolism of Baricitinib can be decreased when combined with Ciprofloxacin.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Encorafenib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Ciprofloxacin.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01GB14, plazomicin, Ciprofloxacin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Ciprofloxacin.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be decreased when combined with Ciprofloxacin.]
[P01BA07, tafenoquine, The excretion of Ciprofloxacin can be decreased when combined with Tafenoquine.]
[A16AX14, migalastat, Ciprofloxacin may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Stiripentol can be decreased when combined with Ciprofloxacin.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Ciprofloxacin.]
[J01AA13, eravacycline, The metabolism of Eravacycline can be decreased when combined with Ciprofloxacin.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Ciprofloxacin.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Ciprofloxacin.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ciprofloxacin.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Ciprofloxacin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Ciprofloxacin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may increase the neuroexcitatory activities of Ciprofloxacin.]
[R03DA02, oxtriphylline, The serum concentration of Oxtriphylline can be increased when it is combined with Ciprofloxacin.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Ciprofloxacin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Ciprofloxacin.]
[L01AD01, carmustine, The metabolism of Carmustine can be decreased when combined with Ciprofloxacin.]
[L01EX12, larotrectinib, The metabolism of Larotrectinib can be decreased when combined with Ciprofloxacin.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Amifampridine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Ciprofloxacin.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Ciprofloxacin.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Cilazapril is combined with Ciprofloxacin.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Ciprofloxacin.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Ciprofloxacin.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Ciprofloxacin.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Ciprofloxacin is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Clarithromycin.]
[N06BA14, solriamfetol, Ciprofloxacin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Ciprofloxacin.]
[N05BA09, clobazam, The metabolism of Clobazam can be decreased when combined with Ciprofloxacin.]
[H02AB14, cloprednol, The risk or severity of tendinopathy can be increased when Cloprednol is combined with Ciprofloxacin.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Ubidecarenone.]
[V03AE07, calcium acetate, Calcium acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Candesartan is combined with Ciprofloxacin.]
[A12CC06, magnesium lactate, Magnesium lactate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of tendinopathy can be increased when Cortivazol is combined with Ciprofloxacin.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Ciprofloxacin.]
[L01FX14, polatuzumab vedotin, The metabolism of Polatuzumab vedotin can be decreased when combined with Ciprofloxacin.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XX66, selinexor, The metabolism of Selinexor can be decreased when combined with Ciprofloxacin.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Ciprofloxacin.]
[J01CF03, methicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Meticillin.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Ciprofloxacin.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Ciprofloxacin.]
[L04AA44, upadacitinib, The metabolism of Upadacitinib can be decreased when combined with Ciprofloxacin.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Ciprofloxacin.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Ciprofloxacin.]
[N07XX11, pitolisant, Ciprofloxacin may increase the QTc-prolonging activities of Pitolisant.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Ciprofloxacin.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Ciprofloxacin.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Ciprofloxacin.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Ciprofloxacin.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Ciprofloxacin.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofloxacin.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Ciprofloxacin.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Ciprofloxacin.]
[G03DB05, demegestone, The metabolism of Demegestone can be decreased when combined with Ciprofloxacin.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Ciprofloxacin.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Ciprofloxacin.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Ciprofloxacin.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Ciprofloxacin.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Ciprofloxacin.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[M09AX08, golodirsen, Ciprofloxacin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Ciprofloxacin.]
[L01FX13, enfortumab vedotin, The metabolism of Enfortumab vedotin can be decreased when combined with Ciprofloxacin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ciprofloxacin.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Ciprofloxacin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Ciprofloxacin.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Ciprofloxacin.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Ciprofloxacin.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Ciprofloxacin.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be decreased when combined with Ciprofloxacin.]
[J05AB16, remdesivir, The metabolism of Remdesivir can be decreased when combined with Ciprofloxacin.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Ciprofloxacin.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be decreased when combined with Ciprofloxacin.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Ciprofloxacin.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be decreased when combined with Ciprofloxacin.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Ciprofloxacin.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Ciprofloxacin.]
[R02AA03, dichlorobenzyl alcohol, Ciprofloxacin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The metabolism of Dienogest can be decreased when combined with Ciprofloxacin.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Ciprofloxacin.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Ciprofloxacin.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Ciprofloxacin.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Ciprofloxacin.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Ciprofloxacin.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Ciprofloxacin.]
[V03AE03, lanthanum carbonate, Lanthanum carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Ciprofloxacin.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be decreased when combined with Ciprofloxacin.]
[L01EH03, tucatinib, The excretion of Ciprofloxacin can be decreased when combined with Tucatinib.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be increased when it is combined with Ciprofloxacin.]
[D07XB03, fluprednidene, The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Ciprofloxacin.]
[M01AC04, droxicam, Droxicam may increase the neuroexcitatory activities of Ciprofloxacin.]
[L01EX19, ripretinib, The metabolism of Ripretinib can be decreased when combined with Ciprofloxacin.]
[V08CA05, mangafodipir, Ciprofloxacin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be increased when it is combined with Ciprofloxacin.]
[M02AA27, dexketoprofen, Dexketoprofen may increase the neuroexcitatory activities of Ciprofloxacin.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Ciprofloxacin.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Dyclonine.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be increased when it is combined with Ciprofloxacin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Ciprofloxacin.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Ciprofloxacin.]
[J05AX29, fostemsavir, The metabolism of Fostemsavir can be decreased when combined with Ciprofloxacin.]
[M09AX10, risdiplam, The serum concentration of Ciprofloxacin can be increased when it is combined with Risdiplam.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be increased when it is combined with Ciprofloxacin.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Pralsetinib can be decreased when combined with Ciprofloxacin.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Ciprofloxacin.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Ciprofloxacin.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Ciprofloxacin.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Ciprofloxacin.]
[A11CC05, cholecalciferol, The metabolism of Cholecalciferol can be decreased when combined with Ciprofloxacin.]
[N02BA07, ethenzamide, Ethenzamide may increase the neuroexcitatory activities of Ciprofloxacin.]
[N02BA03, choline salicylate, Ciprofloxacin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The metabolism of Vinpocetine can be decreased when combined with Ciprofloxacin.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be decreased when combined with Ciprofloxacin.]
[M01AB08, etodolac, Etodolac may increase the neuroexcitatory activities of Ciprofloxacin.]
[M02AA06, etofenamate, Etofenamate may increase the neuroexcitatory activities of Ciprofloxacin.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Etofibrate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Ciprofloxacin.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Ciprofloxacin.]
[M01AX25, chondroitin sulfates, Ciprofloxacin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be decreased when combined with Ciprofloxacin.]
[L01EX21, tepotinib, The metabolism of Tepotinib can be decreased when combined with Ciprofloxacin.]
[V03AF12, trilaciclib, The excretion of Ciprofloxacin can be decreased when combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Felbamate can be decreased when combined with Ciprofloxacin.]
[M01AE05, fenbufen, Fenbufen may increase the neuroexcitatory activities of Ciprofloxacin.]
[N06BA10, fenethylline, The serum concentration of Fenethylline can be increased when it is combined with Ciprofloxacin.]
[C01CA19, fenoldopam, Ciprofloxacin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Ciprofloxacin.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ciprofloxacin.]
[R03BA03, flunisolide, The risk or severity of tendinopathy can be increased when Flunisolide is combined with Ciprofloxacin.]
[N02BG07, flupirtine, Ciprofloxacin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Ciprofloxacin.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Ciprofloxacin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Ciprofloxacin.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Ciprofloxacin.]
[V08CA04, gadoteridol, Ciprofloxacin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Ciprofloxacin.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Cinoxacin.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Ciprofloxacin.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Ciprofloxacin.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Ciprofloxacin.]
[S02BA08, fluocinolone acetonide, The risk or severity of tendinopathy can be increased when Fluocinolone acetonide is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Ciprofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Citalopram.]
[J02AX07, ibrexafungerp, The metabolism of Ibrexafungerp can be decreased when combined with Ciprofloxacin.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Ciprofloxacin.]
[L04AA48, belumosudil, The metabolism of Belumosudil can be decreased when combined with Ciprofloxacin.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Ciprofloxacin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The metabolism of Tisotumab vedotin can be decreased when combined with Ciprofloxacin.]
[N02CD07, atogepant, The metabolism of Atogepant can be decreased when combined with Ciprofloxacin.]
[L04AA59, avacopan, The metabolism of Avacopan can be decreased when combined with Ciprofloxacin.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Ciprofloxacin.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Ciprofloxacin.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Ciprofloxacin.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Ciprofloxacin.]
[N06AX25, St. John's wort extract, The metabolism of St. John's Wort can be decreased when combined with Ciprofloxacin.]
[L01EA06, asciminib, The metabolism of Asciminib can be decreased when combined with Ciprofloxacin.]
[L02BG06, exemestane, The metabolism of Exemestane can be decreased when combined with Ciprofloxacin.]
[J05AX10, maribavir, The metabolism of Maribavir can be decreased when combined with Ciprofloxacin.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Ciprofloxacin.]
[C10AB01, clofibrate, The metabolism of Clofibrate can be decreased when combined with Ciprofloxacin.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be decreased when combined with Ciprofloxacin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be increased when it is combined with Ciprofloxacin.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Ciprofloxacin.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be decreased when combined with Ciprofloxacin.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Ciprofloxacin.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Ciprofloxacin.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Ciprofloxacin.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Ciprofloxacin.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Ciprofloxacin.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Ciprofloxacin.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Granisetron.]
[J01CF02, cloxacillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Cloxacillin.]
[N05AH02, clozapine, The serum concentration of Clozapine can be increased when it is combined with Ciprofloxacin.]
[L01EN04, futibatinib, The metabolism of Futibatinib can be decreased when combined with Ciprofloxacin.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Ciprofloxacin.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Ciprofloxacin.]
[J01GB12, arbekacin, Ciprofloxacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Cocaine.]
[M09AX11, palovarotene, The metabolism of Palovarotene can be decreased when combined with Ciprofloxacin.]
[M01AX13, proquazone, Proquazone may increase the neuroexcitatory activities of Ciprofloxacin.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Ciprofloxacin.]
[J01CA18, hetacillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Hetacillin.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Ciprofloxacin.]
[J01XB01, colistin, Ciprofloxacin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Ciprofloxacin.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ciprofloxacin.]
[A04AA03, tropisetron, Ciprofloxacin may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Ciprofloxacin.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may increase the neuroexcitatory activities of Ciprofloxacin.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Ciprofloxacin.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Ciprofloxacin.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of tendinopathy can be increased when Ciclesonide is combined with Ciprofloxacin.]
[B01AC10, indobufen, Indobufen may increase the neuroexcitatory activities of Ciprofloxacin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Desloratadine.]
[J05AB14, valganciclovir, Ciprofloxacin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[J05AF09, emtricitabine, The excretion of Emtricitabine can be decreased when combined with Ciprofloxacin.]
[C05BB03, invert sugar, Ciprofloxacin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Ciprofloxacin may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Ciprofloxacin may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Ciprofloxacin may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Ciprofloxacin may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Ciprofloxacin.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Ciprofloxacin.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Ciprofloxacin.]
[J02AC02, itraconazole, The metabolism of Itraconazole can be decreased when combined with Ciprofloxacin.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Ciprofloxacin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Ketazolam can be decreased when combined with Ciprofloxacin.]
[M01AA06, kebuzone, Kebuzone may increase the neuroexcitatory activities of Ciprofloxacin.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Posaconazole can be decreased when combined with Ciprofloxacin.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Ciprofloxacin.]
[C08CA09, lacidipine, The metabolism of Lacidipine can be decreased when combined with Ciprofloxacin.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Ciprofloxacin.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ciprofloxacin.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Nafarelin.]
[S01BA03, cortisone, The risk or severity of tendinopathy can be increased when Cortisone is combined with Ciprofloxacin.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Ciprofloxacin.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be decreased when combined with Ciprofloxacin.]
[M01AB09, lonazolac, Lonazolac may increase the neuroexcitatory activities of Ciprofloxacin.]
[R06AX13, loratadine, The metabolism of Loratadine can be decreased when combined with Ciprofloxacin.]
[M02AA31, loxoprofen, Loxoprofen may increase the neuroexcitatory activities of Ciprofloxacin.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Ciprofloxacin.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The metabolism of Manidipine can be decreased when combined with Ciprofloxacin.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Mebeverine.]
[H02AB15, meprednisone, The risk or severity of tendinopathy can be increased when Meprednisone is combined with Ciprofloxacin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Ciprofloxacin.]
[J01DH02, meropenem, Ciprofloxacin may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Adenosine.]
[J01CA14, methampicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Metampicillin.]
[C04AX01, cyclandelate, The metabolism of Cyclandelate can be decreased when combined with Ciprofloxacin.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ciprofloxacin.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Ciprofloxacin.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA03, midecamycin, The metabolism of Midecamycin can be decreased when combined with Ciprofloxacin.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Ciprofloxacin.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Ciprofloxacin.]
[S01XA18, cyclosporine, Cyclosporine may increase the nephrotoxic activities of Ciprofloxacin.]
[N06BA07, modafinil, The metabolism of Modafinil can be decreased when combined with Ciprofloxacin.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ciprofloxacin.]
[C09AA13, moexipril, The risk or severity of hyperkalemia can be increased when Moexipril is combined with Ciprofloxacin.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Ciprofloxacin.]
[M02AA02, mofebutazone, Mofebutazone may increase the neuroexcitatory activities of Ciprofloxacin.]
[M01AX22, morniflumate, Morniflumate may increase the neuroexcitatory activities of Ciprofloxacin.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Ciprofloxacin.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Cytarabine.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Ciprofloxacin.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Ciprofloxacin.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Ciprofloxacin.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Ciprofloxacin.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Ciprofloxacin.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Ciprofloxacin.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Ciprofloxacin.]
[N07BB05, nalmefene, Ciprofloxacin may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Ciprofloxacin.]
[S01GX04, nedocromil, Ciprofloxacin may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Nefazodone can be decreased when combined with Ciprofloxacin.]
[C01DX16, nicorandil, Ciprofloxacin may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Ciprofloxacin may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The metabolism of Tiagabine can be decreased when combined with Ciprofloxacin.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be decreased when combined with Ciprofloxacin.]
[C01CA23, theodrenaline, The serum concentration of Theodrenaline can be increased when it is combined with Ciprofloxacin.]
[M03AC11, cisatracurium, Ciprofloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Ciprofloxacin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Ciprofloxacin.]
[A07EC03, olsalazine, Olsalazine may increase the neuroexcitatory activities of Ciprofloxacin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Ciprofloxacin.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of tendinopathy can be increased when Desoximetasone is combined with Ciprofloxacin.]
[H02AA03, desoxycorticosterone, The risk or severity of tendinopathy can be increased when Desoxycortone is combined with Ciprofloxacin.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C09XA02, aliskiren, The metabolism of Aliskiren can be decreased when combined with Ciprofloxacin.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ciprofloxacin.]
[M01AE12, oxaprozin, Oxaprozin may increase the neuroexcitatory activities of Ciprofloxacin.]
[S03BA01, dexamethasone, The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Ciprofloxacin.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be decreased when combined with Ciprofloxacin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Ciprofloxacin.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Ciprofloxacin.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Ciprofloxacin.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Ciprofloxacin.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Ciprofloxacin.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Ciprofloxacin.]
[C01DA05, pentaerythritol tetranitrate, Ciprofloxacin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, The serum concentration of Pentifylline can be increased when it is combined with Ciprofloxacin.]
[P03AC04, permethrin, Ciprofloxacin may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Ciprofloxacin.]
[J01CE05, phenethicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Pheneticillin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Cinchocaine.]
[R05DA08, pholcodine, Ciprofloxacin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Ciprofloxacin.]
[J01CF01, dicloxacillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ciprofloxacin.]
[A03AA07, dicyclomine, Ciprofloxacin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02DG01, pinacidil, The metabolism of Pinacidil can be decreased when combined with Ciprofloxacin.]
[A03AX04, pinaverium, The metabolism of Pinaverium can be decreased when combined with Ciprofloxacin.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Ciprofloxacin.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Ciprofloxacin.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be increased when it is combined with Ciprofloxacin.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Ciprofloxacin.]
[C08CA03, isradipine, The metabolism of Isradipine can be decreased when combined with Ciprofloxacin.]
[D07XC04, diflucortolone, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Ciprofloxacin.]
[N02BA11, diflunisal, Diflunisal may increase the neuroexcitatory activities of Ciprofloxacin.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Ciprofloxacin.]
[C01AA05, digoxin, Ciprofloxacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Ciprofloxacin.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Ciprofloxacin.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Ciprofloxacin.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Atazanavir can be decreased when combined with Ciprofloxacin.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Ciprofloxacin.]
[H03BC01, potassium perchlorate, Ciprofloxacin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Ciprofloxacin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Ciprofloxacin.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Ciprofloxacin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Ciprofloxacin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N06BC02, propentofylline, The serum concentration of Propentofylline can be increased when it is combined with Ciprofloxacin.]
[J01CE03, propicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Propicillin.]
[N02BB04, propyphenazone, Propyphenazone may increase the neuroexcitatory activities of Ciprofloxacin.]
[M01AB14, proglumetacin, Proglumetacin may increase the neuroexcitatory activities of Ciprofloxacin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Proparacaine.]
[R03DA03, proxyphylline, The serum concentration of Proxyphylline can be increased when it is combined with Ciprofloxacin.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Ciprofloxacin.]
[C09AA06, quinapril, Quinapril can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Ciprofloxacin.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Ciprofloxacin.]
[S01AX06, resorcinol, Ciprofloxacin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Disopyramide.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be decreased when combined with Ciprofloxacin.]
[S02AA12, rifamycin SV, The excretion of Ciprofloxacin can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Rifapentine can be decreased when combined with Ciprofloxacin.]
[N07XX02, riluzole, The metabolism of Riluzole can be decreased when combined with Ciprofloxacin.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Ciprofloxacin.]
[R06AE09, levocetirizine, The metabolism of Levocetirizine can be decreased when combined with Ciprofloxacin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Ciprofloxacin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Ciprofloxacin.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be decreased when combined with Ciprofloxacin.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Ciprofloxacin.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Ciprofloxacin.]
[J05AE07, fosamprenavir, The metabolism of Fosamprenavir can be decreased when combined with Ciprofloxacin.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be decreased when combined with Ciprofloxacin.]
[S01BC05, ketorolac, Ketorolac may increase the neuroexcitatory activities of Ciprofloxacin.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Ciprofloxacin.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be decreased when combined with Ciprofloxacin.]
[N02BA06, salsalate, Salsalate may increase the neuroexcitatory activities of Ciprofloxacin.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be decreased when combined with Ciprofloxacin.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C01CA07, dobutamine, Ciprofloxacin may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Domperidone.]
[C01CA04, dopamine, Ciprofloxacin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Ciprofloxacin.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Ciprofloxacin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Ciprofloxacin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ciprofloxacin.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Ciprofloxacin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Ciprofloxacin.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Ciprofloxacin.]
[A08AA10, sibutramine, The metabolism of Sibutramine can be decreased when combined with Ciprofloxacin.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Ciprofloxacin.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CA02, sodium sulfate, Ciprofloxacin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Spirapril is combined with Ciprofloxacin.]
[G03DB01, dydrogesterone, The metabolism of Dydrogesterone can be decreased when combined with Ciprofloxacin.]
[R03DA01, dyphylline, The serum concentration of Dyphylline can be increased when it is combined with Ciprofloxacin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sultopride.]
[N02CC01, sumatriptan, Ciprofloxacin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Ciprofloxacin may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Ciprofloxacin.]
[H01AA01, corticotropin, The risk or severity of tendinopathy can be increased when Corticotropin is combined with Ciprofloxacin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Temafloxacin.]
[J01CA17, temocillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Temocillin.]
[L01AX03, temozolomide, Ciprofloxacin may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may increase the neuroexcitatory activities of Ciprofloxacin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Ciprofloxacin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Terodiline.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Emetine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Ciprofloxacin.]
[C09AA02, enalapril, The risk or severity of hyperkalemia can be increased when Enalapril is combined with Ciprofloxacin.]
[M01AG02, tolfenamic acid, The metabolism of Tolfenamic acid can be decreased when combined with Ciprofloxacin.]
[N06AG03, toloxatone, Ciprofloxacin may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ciprofloxacin.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Ciprofloxacin.]
[H02CA01, trilostane, The risk or severity of tendinopathy can be increased when Trilostane is combined with Ciprofloxacin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ciprofloxacin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ciprofloxacin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Ciprofloxacin.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Ciprofloxacin.]
[N06AX16, venlafaxine, The metabolism of Venlafaxine can be decreased when combined with Ciprofloxacin.]
[C08CA12, mepirodipine, The metabolism of Barnidipine can be decreased when combined with Ciprofloxacin.]
[B05XA12, zinc chloride, Zinc chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B05XA18, zinc sulfate, Zinc sulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Zofenopril is combined with Ciprofloxacin.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Ciprofloxacin.]
[M01AB04, zomepirac, The metabolism of Zomepirac can be decreased when combined with Ciprofloxacin.]
[N03AX15, zonisamide, The metabolism of Zonisamide can be decreased when combined with Ciprofloxacin.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Ciprofloxacin.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Ciprofloxacin.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Ciprofloxacin.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C02AC02, guanfacine, The metabolism of Guanfacine can be decreased when combined with Ciprofloxacin.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Ciprofloxacin.]
[G02AB03, ergonovine, The metabolism of Ergometrine can be decreased when combined with Ciprofloxacin.]
[C04AE01, ergoloid mesylates, USP, The metabolism of Ergoloid mesylate can be decreased when combined with Ciprofloxacin.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Ciprofloxacin.]
[L03AX05, pidotimod, Ciprofloxacin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Ciprofloxacin.]
[N05CD04, estazolam, The metabolism of Estazolam can be decreased when combined with Ciprofloxacin.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Ciprofloxacin.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Ciprofloxacin.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Ciprofloxacin.]
[L01XX11, estramustine, The metabolism of Estramustine can be decreased when combined with Ciprofloxacin.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Ciprofloxacin.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of tendinopathy can be increased when Fluticasone furoate is combined with Ciprofloxacin.]
[R03BA05, fluticasone, The risk or severity of tendinopathy can be increased when Fluticasone is combined with Ciprofloxacin.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Ciprofloxacin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Ciprofloxacin.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ibutilide.]
[N03AD01, ethosuximide, The metabolism of Ethosuximide can be decreased when combined with Ciprofloxacin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Ciprofloxacin.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Ciprofloxacin.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Ciprofloxacin.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Ciprofloxacin.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Ciprofloxacin.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Ciprofloxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Ciprofloxacin.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Terfenadine.]
[P01AX07, trimetrexate, Ciprofloxacin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Ciprofloxacin may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, The metabolism of Fluvoxamine can be decreased when combined with Ciprofloxacin.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Ciprofloxacin.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Ciprofloxacin.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ciprofloxacin.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Ciprofloxacin.]
[M01CB01, gold sodium thiomalate, Ciprofloxacin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Ciprofloxacin may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ciprofloxacin.]
[A16AA01, levocarnitine, Ciprofloxacin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Ciprofloxacin.]
[C08CA02, felodipine, The metabolism of Felodipine can be decreased when combined with Ciprofloxacin.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Ciprofloxacin.]
[M01AE04, fenoprofen, Fenoprofen may increase the neuroexcitatory activities of Ciprofloxacin.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Ciprofloxacin.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ciprofloxacin.]
[L01BB06, clofarabine, Ciprofloxacin may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ciprofloxacin.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Ciprofloxacin.]
[G04BD02, flavoxate, Ciprofloxacin may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Ciprofloxacin.]
[N02BG04, floctafenine, Floctafenine may increase the neuroexcitatory activities of Ciprofloxacin.]
[J01CF05, floxacillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Flucloxacillin.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ciprofloxacin.]
[J02AX01, flucytosine, Ciprofloxacin may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of tendinopathy can be increased when Fludrocortisone is combined with Ciprofloxacin.]
[V03AB25, flumazenil, Ciprofloxacin may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of tendinopathy can be increased when Flumethasone is combined with Ciprofloxacin.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Ciprofloxacin.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Ciprofloxacin.]
[D07AC08, fluocinonide, The risk or severity of tendinopathy can be increased when Fluocinonide is combined with Ciprofloxacin.]
[H02AB03, fluocortolone, The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Ciprofloxacin.]
[V03AZ01, ethanol, The metabolism of Ethanol can be decreased when combined with Ciprofloxacin.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Ciprofloxacin.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ciprofloxacin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Flupentixol.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be decreased when combined with Ciprofloxacin.]
[S01BC04, flurbiprofen, Flurbiprofen may increase the neuroexcitatory activities of Ciprofloxacin.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Ciprofloxacin.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[S02AA17, fosfomycin, Ciprofloxacin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Ciprofloxacin.]
[J05AE10, darunavir, The metabolism of Darunavir can be decreased when combined with Ciprofloxacin.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Ciprofloxacin.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Ciprofloxacin.]
[C08DA02, gallopamil, The metabolism of Gallopamil can be decreased when combined with Ciprofloxacin.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The metabolism of Gemfibrozil can be decreased when combined with Ciprofloxacin.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ciprofloxacin.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Ciprofloxacin.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Ciprofloxacin.]
[C01CA21, cafedrine, The serum concentration of Cafedrine can be increased when it is combined with Ciprofloxacin.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Ciprofloxacin.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Ciprofloxacin.]
[A12AA13, calcium citrate, Calcium citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12AA10, calcium gluceptate, Calcium glucoheptonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12AA05, calcium lactate, Calcium lactate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ciprofloxacin.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be decreased when combined with Ciprofloxacin.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be decreased when combined with Ciprofloxacin.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Ciprofloxacin.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Ciprofloxacin.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Ciprofloxacin.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Ciprofloxacin.]
[N05CM18, dexmedetomidine, Ciprofloxacin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Ciprofloxacin.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Ciprofloxacin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Ciprofloxacin.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ciprofloxacin.]
[M01CB04, aurothioglucose, Ciprofloxacin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Ciprofloxacin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Ciprofloxacin.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Ciprofloxacin.]
[S01EX01, guanethidine, Ciprofloxacin may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ciprofloxacin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Ciprofloxacin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Quetiapine.]
[N06BX13, idebenone, Ciprofloxacin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Ciprofloxacin.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Ciprofloxacin.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of hyperkalemia can be increased when Losartan is combined with Ciprofloxacin.]
[B05CB03, magnesium citrate, Magnesium citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC03, magnesium gluconate, Magnesium gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Ciprofloxacin.]
[A07EC02, mesalamine, Mesalazine may increase the neuroexcitatory activities of Ciprofloxacin.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Ciprofloxacin.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Nilvadipine.]
[M02AA26, nimesulide, The metabolism of Nimesulide can be decreased when combined with Ciprofloxacin.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Perindopril is combined with Ciprofloxacin.]
[C02DB02, hydralazine, Ciprofloxacin may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Ciprofloxacin.]
[S02BA01, hydrocortisone, The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Ciprofloxacin.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Ciprofloxacin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[G04BD06, propiverine, The metabolism of Propiverine can be decreased when combined with Ciprofloxacin.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Ciprofloxacin.]
[B05AA07, hetastarch, Ciprofloxacin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[G03DA03, 17-alpha-hydroxyprogesterone, The metabolism of Hydroxyprogesterone can be decreased when combined with Ciprofloxacin.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Rifabutin can be decreased when combined with Ciprofloxacin.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Risedronic acid.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Ciprofloxacin.]
[B05XA08, sodium acetate, Ciprofloxacin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Ciprofloxacin.]
[N01AH03, sufentanil, The metabolism of Sufentanil can be decreased when combined with Ciprofloxacin.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Ciprofloxacin.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Ciprofloxacin.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of tendinopathy can be increased when Tixocortol is combined with Ciprofloxacin.]
[M03BX02, tizanidine, The risk or severity of hypotension can be increased when Ciprofloxacin is combined with Tizanidine.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Ciprofloxacin.]
[C03BA11, indapamide, The metabolism of Indapamide can be decreased when combined with Ciprofloxacin.]
[S01BC01, indomethacin, Indomethacin may increase the neuroexcitatory activities of Ciprofloxacin.]
[A16AX05, zinc acetate, Zinc acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CB02, zinc gluconate, Zinc gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A11HA07, inositol, Ciprofloxacin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be decreased when combined with Ciprofloxacin.]
[S01XA28, varenicline, Ciprofloxacin may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Ciprofloxacin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Ciprofloxacin.]
[N05CH02, ramelteon, The serum concentration of Ramelteon can be increased when it is combined with Ciprofloxacin.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Ciprofloxacin.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Ciprofloxacin.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Ciprofloxacin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Anagrelide.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Ciprofloxacin.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Stavudine.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Ciprofloxacin.]
[P01AX06, atovaquone, The metabolism of Atovaquone can be decreased when combined with Ciprofloxacin.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Imidapril is combined with Ciprofloxacin.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Ciprofloxacin.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Isoniazid.]
[J05AX05, inosine pranobex, Ciprofloxacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Ciprofloxacin.]
[C01DA14, isosorbide mononitrate, Ciprofloxacin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, The metabolism of Isotretinoin can be decreased when combined with Ciprofloxacin.]
[P02CF01, ivermectin, The metabolism of Ivermectin can be decreased when combined with Ciprofloxacin.]
[N06AX18, reboxetine, The metabolism of Reboxetine can be decreased when combined with Ciprofloxacin.]
[S01AA24, kanamycin, Ciprofloxacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Ciprofloxacin.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Ciprofloxacin.]
[B01AC22, prasugrel, Ciprofloxacin may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Ketoconazole can be decreased when combined with Ciprofloxacin.]
[H02CA04, levoketoconazole, The metabolism of Levoketoconazole can be decreased when combined with Ciprofloxacin.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be decreased when combined with Ciprofloxacin.]
[M02AA10, ketoprofen, Ketoprofen may increase the neuroexcitatory activities of Ciprofloxacin.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mizolastine.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Ciprofloxacin.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may increase the neuroexcitatory activities of Ciprofloxacin.]
[C07AG01, labetalol, Ciprofloxacin may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ciprofloxacin.]
[J05AX09, maraviroc, The metabolism of Maraviroc can be decreased when combined with Ciprofloxacin.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Ciprofloxacin.]
[A06AX03, lubiprostone, Ciprofloxacin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Ciprofloxacin.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[R05CB06, ambroxol, The metabolism of Ambroxol can be decreased when combined with Ciprofloxacin.]
[J01CA11, amdinocillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The serum concentration of Ciprofloxacin can be increased when it is combined with Pivmecillinam.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be decreased when combined with Ciprofloxacin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Lidocaine.]
[C08EX01, lidoflazine, The metabolism of Lidoflazine can be decreased when combined with Ciprofloxacin.]
[S01AA21, amikacin, Ciprofloxacin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Ciprofloxacin.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Ciprofloxacin.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Loperamide.]
[N05BA06, lorazepam, The metabolism of Lorazepam can be decreased when combined with Ciprofloxacin.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Ciprofloxacin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Ciprofloxacin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Ciprofloxacin.]
[B05XA11, magnesium chloride, Magnesium chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, Magnesium sulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BA05, pralatrexate, Ciprofloxacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Ciprofloxacin.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Ciprofloxacin.]
[C02BB01, mecamylamine, Ciprofloxacin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.]
[G03DB03, medrogestone, The metabolism of Medrogestone can be decreased when combined with Ciprofloxacin.]
[P01BC02, mefloquine, The metabolism of Mefloquine can be decreased when combined with Ciprofloxacin.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The metabolism of Melatonin can be decreased when combined with Ciprofloxacin.]
[N06DX01, memantine, Ciprofloxacin may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Ciprofloxacin.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Ciprofloxacin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Mepivacaine.]
[G04BX16, tiopronin, Ciprofloxacin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Ciprofloxacin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Ciprofloxacin.]
[N06BA03, methamphetamine, Ciprofloxacin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[N05CM01, methaqualone, The metabolism of Methaqualone can be decreased when combined with Ciprofloxacin.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Lamivudine.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Ciprofloxacin may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be decreased when combined with Ciprofloxacin.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be increased when it is combined with Ciprofloxacin.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ciprofloxacin.]
[D05BA02, methoxsalen, Ciprofloxacin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Methyldopa.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Ciprofloxacin.]
[G02AB01, methylergonovine, The metabolism of Methylergometrine can be decreased when combined with Ciprofloxacin.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be increased when it is combined with Ciprofloxacin.]
[H02AB04, methylprednisolone, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Ciprofloxacin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Ciprofloxacin.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Ciprofloxacin.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Ciprofloxacin.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be decreased when combined with Ciprofloxacin.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be decreased when combined with Ciprofloxacin.]
[V04CD01, metyrapone, Ciprofloxacin may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Ciprofloxacin.]
[J01CA10, mezlocillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Mezlocillin.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Ciprofloxacin.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Ciprofloxacin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Ciprofloxacin.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mifepristone.]
[J05AH01, zanamivir, Ciprofloxacin may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Ciprofloxacin.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Minocycline.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Ciprofloxacin.]
[N06AA09, amitriptyline, Ciprofloxacin may increase the QTc-prolonging activities of Amitriptyline.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Ciprofloxacin.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Ciprofloxacin.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Ciprofloxacin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Ciprofloxacin.]
[G04BA01, ammonium chloride, Ciprofloxacin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Ciprofloxacin.]
[L04AA06, mycophenolic acid, The serum concentration of Mycophenolic acid can be decreased when it is combined with Ciprofloxacin.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Raltegravir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ciprofloxacin.]
[G04CA04, silodosin, The metabolism of Silodosin can be decreased when combined with Ciprofloxacin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ciprofloxacin.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Ciprofloxacin.]
[C07AA12, nadolol, The excretion of Nadolol can be decreased when combined with Ciprofloxacin.]
[J01CA04, amoxicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Amoxicillin.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ciprofloxacin is combined with Ropinirole.]
[J01CF06, nafcillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Nafcillin.]
[V03AB15, naloxone, Ciprofloxacin may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Naltrexone.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Ciprofloxacin.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Ciprofloxacin.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be decreased when combined with Ciprofloxacin.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Ciprofloxacin.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Ciprofloxacin.]
[S03AA01, neomycin, Ciprofloxacin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Ciprofloxacin.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Levosimendan.]
[B01AC17, tirofiban, Ciprofloxacin may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Ciprofloxacin.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Amphotericin B.]
[S01AA19, ampicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Ampicillin.]
[L03AX16, plerixafor, Ciprofloxacin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Ciprofloxacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Desvenlafaxine can be decreased when combined with Ciprofloxacin.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Ciprofloxacin.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[H05BX02, paricalcitol, The metabolism of Paricalcitol can be decreased when combined with Ciprofloxacin.]
[C01CE01, inamrinone, Ciprofloxacin may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Nicardipine can be decreased when combined with Ciprofloxacin.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Ciprofloxacin.]
[M02AA17, niflumic acid, Niflumic acid may increase the neuroexcitatory activities of Ciprofloxacin.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Ciprofloxacin.]
[C08CA07, nisoldipine, The metabolism of Nisoldipine can be decreased when combined with Ciprofloxacin.]
[N05CD02, nitrazepam, The metabolism of Nitrazepam can be decreased when combined with Ciprofloxacin.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be decreased when combined with Ciprofloxacin.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The therapeutic efficacy of Ciprofloxacin can be decreased when used in combination with Nitrofurantoin.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be decreased when combined with Ciprofloxacin.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Ciprofloxacin.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Ciprofloxacin.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Ciprofloxacin.]
[G02CA02, nylidrin, The metabolism of Nylidrin can be decreased when combined with Ciprofloxacin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ciprofloxacin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ofloxacin.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Ciprofloxacin.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Ciprofloxacin.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Ciprofloxacin.]
[J01CF04, oxacillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Oxacillin.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05BA04, oxazepam, Ciprofloxacin may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Ciprofloxacin.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Ciprofloxacin.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Ciprofloxacin.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may increase the neuroexcitatory activities of Ciprofloxacin.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ciprofloxacin.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Asenapine.]
[J04AB30, capreomycin, Ciprofloxacin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be decreased when combined with Ciprofloxacin.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of tendinopathy can be increased when Paramethasone is combined with Ciprofloxacin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ciprofloxacin.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Ciprofloxacin.]
[C07AA23, penbutolol, Ciprofloxacin may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Penicillamine.]
[S01AA14, penicillin G, The serum concentration of Ciprofloxacin can be increased when it is combined with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The serum concentration of Ciprofloxacin can be increased when it is combined with Procaine benzylpenicillin.]
[J01CE02, penicillin V, The serum concentration of Ciprofloxacin can be increased when it is combined with Phenoxymethylpenicillin.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XX08, pentostatin, Ciprofloxacin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The serum concentration of Pentoxifylline can be increased when it is combined with Ciprofloxacin.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Ciprofloxacin.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Ciprofloxacin.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Ciprofloxacin.]
[G04BX06, phenazopyridine, The bioavailability of Ciprofloxacin can be increased when combined with Phenazopyridine.]
[N06AF03, phenelzine, Ciprofloxacin may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Ciprofloxacin.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Ciprofloxacin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ciprofloxacin.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Ciprofloxacin.]
[A08AA01, phentermine, The metabolism of Phentermine can be decreased when combined with Ciprofloxacin.]
[V03AB36, phentolamine, Ciprofloxacin may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may increase the neuroexcitatory activities of Ciprofloxacin.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Ciprofloxacin.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Ciprofloxacin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Ciprofloxacin.]
[B02BA01, vitamin K1, Ciprofloxacin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Ciprofloxacin.]
[C07AA03, pindolol, Ciprofloxacin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Ciprofloxacin.]
[J01CA12, piperacillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Piperacillin.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Saquinavir.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Ciprofloxacin.]
[N06BX03, piracetam, Ciprofloxacin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Ciprofloxacin.]
[S01BC06, piroxicam, Piroxicam may increase the neuroexcitatory activities of Ciprofloxacin.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Grepafloxacin.]
[J01CA02, pivampicillin, The serum concentration of Ciprofloxacin can be increased when it is combined with Pivampicillin.]
[J05AG02, delavirdine, The metabolism of Delavirdine can be decreased when combined with Ciprofloxacin.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Ciprofloxacin.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Ciprofloxacin.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Ciprofloxacin.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The metabolism of Ritonavir can be decreased when combined with Ciprofloxacin.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Ciprofloxacin.]
[B05XA01, potassium chloride, Ciprofloxacin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Ciprofloxacin.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Pitavastatin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Ciprofloxacin.]
[N05BA11, prazepam, The metabolism of Prazepam can be decreased when combined with Ciprofloxacin.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Ciprofloxacin.]
[S03BA02, prednisolone, The risk or severity of tendinopathy can be increased when Prednisolone is combined with Ciprofloxacin.]
[H02AB07, prednisone, The risk or severity of tendinopathy can be increased when Prednisone is combined with Ciprofloxacin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Primaquine can be decreased when combined with Ciprofloxacin.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Ciprofloxacin.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Ciprofloxacin.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Ciprofloxacin.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Ciprofloxacin.]
[G03DB07, promegestone, The metabolism of Promegestone can be decreased when combined with Ciprofloxacin.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Ciprofloxacin.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Ciprofloxacin.]
[A03AB05, propantheline, Ciprofloxacin may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Ciprofloxacin.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Ciprofloxacin.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Ciprofloxacin.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Propylthiouracil.]
[N02CC04, rizatriptan, Ciprofloxacin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Ciprofloxacin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Ciprofloxacin.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ciprofloxacin.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Ciprofloxacin.]
[N07XX07, dalfampridine, Ciprofloxacin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Ciprofloxacin may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Ciprofloxacin.]
[P01BD01, pyrimethamine, The excretion of Ciprofloxacin can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Ciprofloxacin.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Ciprofloxacin.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Ranitidine can be decreased when combined with Ciprofloxacin.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Ciprofloxacin.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[J05AP01, ribavirin, Ciprofloxacin may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may increase the neuroexcitatory activities of Ciprofloxacin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the neuroexcitatory activities of Ciprofloxacin.]
[S01BC08, salicylic acid, Salicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.]
[S01FA02, scopolamine, The metabolism of Scopolamine can be decreased when combined with Ciprofloxacin.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Ciprofloxacin.]
[J01GB08, sisomicin, Ciprofloxacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Ciprofloxacin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Ciprofloxacin may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Ciprofloxacin.]
[C03DA01, spironolactone, Spironolactone may increase the arrhythmogenic activities of Ciprofloxacin.]
[V09AB03, ioflupane I-123, Ciprofloxacin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Ciprofloxacin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Ciprofloxacin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[V04CH02, indigo carmine, Ciprofloxacin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[N05CC01, chloral hydrate, Ciprofloxacin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Valproic acid.]
[A05AA01, chenodeoxycholic acid, The metabolism of Chenodeoxycholic acid can be decreased when combined with Ciprofloxacin.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Alendronic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Ciprofloxacin.]
[D10AX03, azelaic acid, Ciprofloxacin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[A12AA11, calcium pangamate, Calcium pangamate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[M03BX02, tizanidine, Tizanidine - CYP 1A2 inhibitors]
[N05CH02, ramelteon, Ramelteon - specific CYP1A2 inhibitors]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
